Governance
Strategy & Planning
Strategic Plan
2025-2028
PAREA was founded to advance the responsible integration of psychedelic treatments into European healthcare systems.
In its first three years, PAREA has established itself as a central voice for psychedelic therapies in Europe. We've built a community that is grounded in evidence and focused on addressing unmet needs in brain health. Through our efforts, we have successfully brought psychedelic medicines to the attention of key European Union institutions (notably acting as secretariat of the European Parliament Action Group on Psychedelics in Healthcare) and the media, sparking an EU-wide conversation about the potential of these treatments and the challenges that must be addressed to support their development and adoption in medical contexts.
This strategic plan outlines our objectives for 2025–2028. While it's unlikely that the European Medicines Agency will approve psychedelics during this period, we'll focus on maintaining momentum and preparing the groundwork for future approvals.
Work Plan
2025
In 2025, PAREA embarks on its first operational year as a legally recognized entity with a dedicated Board of Directors. Our commitment to transparency, robust governance, and effective financial management sets the foundation for our initiatives. Building on previous achievements, we aim to enhance political engagement, nurture stakeholder relationships, and drive policy reforms to integrate psychedelic therapies into European healthcare systems.
In addition, the recent European Union elections present fresh opportunities to engage with newly elected Members of the European Parliament and EU Commissioners. This transitional phase offers a prime moment for advocacy, allowing PAREA to reinforce its objectives and establish connections with key decision-makers.